作者
Jacob E Berchuck, Francesco Facchinetti, Daniel F DiToro, Islam Baiev, Umair Majeed, Stephanie Reyes, Christopher Chen, Karen Zhang, Reya Sharman, PLS Uson Junior, Jordan Maurer, Rachna T Shroff, Colin C Pritchard, M-J Wu, Daniel VT Catenacci, Milind Javle, Luc Friboulet, Antoine Hollebecque, Nabeel Bardeesy, Andrew X Zhu, JK Lennerz, B Tan, M Borad, AR Parikh, LA Kiedrowski, RK Kelley, K Mody, D Juric, L Goyal
发表日期
2022/12/1
期刊
Annals of Oncology
卷号
33
期号
12
页码范围
1269-1283
出版商
Elsevier
简介
Background
Targeted therapies have transformed clinical management of advanced biliary tract cancer (BTC). Cell-free DNA (cfDNA) analysis is an attractive approach for cancer genomic profiling that overcomes many limitations of traditional tissue-based analysis. We examined cfDNA as a tool to inform clinical management of patients with advanced BTC and generate novel insights into BTC tumor biology.
Patients and methods
We analyzed next-generation sequencing data of 2068 cfDNA samples from 1671 patients with advanced BTC generated with Guardant360. We carried out clinical annotation on a multi-institutional subset (n = 225) to assess intra-patient cfDNA–tumor concordance and the association of cfDNA variant allele fraction (VAF) with clinical outcomes.
Results
Genetic alterations were detected in cfDNA in 84% of patients, with targetable alterations detected in 44% of patients. Fibroblast growth …
学术搜索中的文章
JE Berchuck, F Facchinetti, DF DiToro, I Baiev… - Annals of Oncology, 2022